KLRC2 and neoplasm: There are also certain benefits in using adaptive-like NK cells in immunotherapy: NKG2C+ NK cells are associated with preventing GVHD [28] and demonstrate higher ADCC levels [29,30]; they are also capable of not only destroying malignant HLA-Epos neoplasms, but also have increased allo-reactivity in HLA-incompatible recipients due to the shift of the KIR repertoire towards self-KIRs [15].